General News

by Sophiris

In: General News

No comments

Effective today, Protox Therapeutics Inc. has changed its name to Sophiris Bio, Inc. Trading, which will take place on the Toronto Stock Exchange, is expected to commence under the new name and ticker symbol “SHS” by or shortly after April 5th of this year.

The change is part of an operational realignment that began in 2011 led by Executive Chairman and President Lars Ekman, M.D., Ph.D., to focus on the development of a late-stage, highly targeted treatment for benign prostatic hyperplasia (BPH or enlarged prostate), an unsatisfied market with blockbuster potential. Sophiris, located in San Diego, has recruited a management team that has achieved more than twenty drug approvals and expects to initiate pivotal Phase 3 trials for its lead drug candidate for BPH called PRX302 before the end of 2012.